Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma
M. Yazdanifar, R. Zhou, P. Grover, C. Williams, M. Bose, L. J. Moore, S.-t. Wu, R. Chi, J. Maher, D. Dreau, P. Mukherjee
This study develops a novel tMUC1-targeting CAR T cell therapy for pancreatic ductal adenocarcinoma and shows that combining it with inhibitors of IDO1, COX1/2, and Gal-9 enhances its efficacy against resistant tumors.
bioRxiv · May 20, 2019Cancer Biology